Nanjing Leads Biolabs Co., Ltd. (HKG:9887)
Hong Kong · Delayed Price · Currency is HKD 40.46
-2.48 (-5.78%)
Oct 21, 2026, 2:55 PM HKT
Nanjing Leads Biolabs Revenue
Nanjing Leads Biolabs had revenue of 35.97M CNY in the half year ending June 30, 2026. This brings the company's total for the last twelve months to 213.22M. In the year 2025, Nanjing Leads Biolabs had annual revenue of 177.26M. That makes Nanjing Leads Biolabs the 31,064th largest company in the world by revenue and 1,863rd in Hong Kong.
Revenue (ttm)
213.22M CNY
Revenue Growth
n/a
P/S Ratio
34.04
Revenue / Employee
823.26K CNY
Employees
259
Market Cap
7.89B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 177.26M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 8.87M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Nanjing Leads Biolabs News
- 5 days ago - Leads Biolabs Doses First Patient In Phase 1b/2 Opamtistomig Trial In Colorectal Cancer - Nasdaq
- 8 days ago - FDA Grants Fast Track Tag To Leads Biolabs' Opamtistomig In Biliary Tract Cancer - Nasdaq
- 4 weeks ago - Nanjing Leads Biolabs To Present Opamtistomig Phase IIb Study At ESMO 2026 - Nasdaq
- 7 weeks ago - Nanjing Leads Biolabs Earnings release: H1 2026 - Filings
- 7 weeks ago - Nanjing Leads Biolabs Quarterly report: H1 2026 - Filings
- 7 weeks ago - Nanjing Leads Biolabs Slides: H1 2026 - Filings
- 6 months ago - Nanjing Leads Biolabs Annual report: H2 2025 - Filings
- 6 months ago - Nanjing Leads Biolabs Earnings release: H2 2025 - Filings